Merck Inventory 2010-2024 | MRK

Merck inventory from 2010 to 2024. Inventory can be defined as the total value of inventories in all stages of completion.
  • Merck inventory for the quarter ending September 30, 2024 was $6.244B, a 1.84% increase year-over-year.
  • Merck inventory for 2023 was $6.358B, a 7.56% increase from 2022.
  • Merck inventory for 2022 was $5.911B, a 0.71% decline from 2021.
  • Merck inventory for 2021 was $5.953B, a 7.18% increase from 2020.
Merck Annual Inventory
(Millions of US $)
2023 $6,358
2022 $5,911
2021 $5,953
2020 $5,554
2019 $5,978
2018 $5,440
2017 $5,096
2016 $4,866
2015 $4,700
2014 $5,571
2013 $6,226
2012 $6,535
2011 $6,254
2010 $5,868
2009 $8,048
Merck Quarterly Inventory
(Millions of US $)
2024-09-30 $6,244
2024-06-30 $6,469
2024-03-31 $6,510
2023-12-31 $6,358
2023-09-30 $6,131
2023-06-30 $5,930
2023-03-31 $5,863
2022-12-31 $5,911
2022-09-30 $5,614
2022-06-30 $5,535
2022-03-31 $5,774
2021-12-31 $5,953
2021-09-30 $5,603
2021-06-30 $5,499
2021-03-31 $6,402
2020-12-31 $5,554
2020-09-30 $6,128
2020-06-30 $6,056
2020-03-31 $5,846
2019-12-31 $5,978
2019-09-30 $5,855
2019-06-30 $5,847
2019-03-31 $5,712
2018-12-31 $5,440
2018-09-30 $5,416
2018-06-30 $5,178
2018-03-31 $5,382
2017-12-31 $5,096
2017-09-30 $5,263
2017-06-30 $5,407
2017-03-31 $5,146
2016-12-31 $4,866
2016-09-30 $5,244
2016-06-30 $5,248
2016-03-31 $5,102
2015-12-31 $4,700
2015-09-30 $5,123
2015-06-30 $5,306
2015-03-31 $5,539
2014-12-31 $5,571
2014-09-30 $5,819
2014-06-30 $6,136
2014-03-31 $6,376
2013-12-31 $6,226
2013-09-30 $6,741
2013-06-30 $6,766
2013-03-31 $6,773
2012-12-31 $6,535
2012-09-30 $6,731
2012-06-30 $6,249
2012-03-31 $6,339
2011-12-31 $6,254
2011-09-30 $6,239
2011-06-30 $6,225
2011-03-31 $6,057
2010-12-31 $5,868
2010-09-30 $6,264
2010-06-30 $6,244
2010-03-31 $6,825
2009-12-31 $8,048
2009-09-30 $2,096
2009-06-30 $2,155
2009-03-31 $2,128
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $244.211B $60.115B
Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda, Simponi , Januvia and Janumet, Bridion, Isentress, ProQuad, Gardasil, Pneumovax 23, RotaTeq and Belsomra. Merck made its biggest acquisition of Schering-Plough and sold off its Consumer Care business to Bayer. Other key acquisitions include Idenix Pharmaceuticals, Cubist Pharmaceuticals, Rigontec, ArQule and Acceleron Pharma. IMerck spun off products from its Women's Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon & Co.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $692.744B 71.75
Novo Nordisk (NVO) Denmark $460.555B 33.21
Johnson & Johnson (JNJ) United States $368.366B 14.94
AbbVie (ABBV) United States $294.353B 15.49
Novartis AG (NVS) Switzerland $211.084B 14.03
AstraZeneca (AZN) United Kingdom $197.819B 16.83
Pfizer (PFE) United States $142.241B 9.73
Sanofi (SNY) $121.816B 11.03
Innoviva (INVA) United States $1.195B 9.94